Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai psychiatric multicenter study

Psychiatry and Clinical Neurosciences

Volumn 63, Issue 3, 2009, Pages 322-328

  Okugawa, Gaku ^a   Kato, Masaki ^a   Wakeno, Masataka ^a   Koh, Jun ^b   Morikawa, Masayuki ^c   Matsumoto, Naoki ^d   Shinosaki, Kazuhiro ^d   Yoneda, Hiroshi ^b   Kishimoto, Toshifumi ^c   Kinoshita, Toshihiko ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antipsychotics; Neuroleptic; Perospirone; Risperidone; Schizophrenia

Indexed keywords

ALPRAZOLAM; BIPERIDEN; BROMAZEPAM; BROTIZOLAM; CARBAMAZEPINE; CLOBAZAM; DIAZEPAM; ESTAZOLAM; FLUNITRAZEPAM; FLUVOXAMINE; LITHIUM; NITRAZEPAM; PEROSPIRONE; PROMETHAZINE; QUAZEPAM; RISPERIDONE; TRIAZOLAM; VALPROIC ACID; ZOPICLONE;

ADULT; ANXIETY; ARTICLE; BLUNTED AFFECT; BODY WEIGHT; BRADYCARDIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; FEMALE; HUMANS; ISOINDOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES;

EID: 65649131595     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2009.01947.x     Document Type: Article

References (15)

1. Sekine Y, Ouchi Y, Takei N et al. Perospirone is a new generation antipsychotic: Evidence from a positron emission tomography study of serotonin 2 and d2 receptor occupancy in the living human brain. J. Clin. Psychopharmacol. 2006 26 : 531 533. (Pubitemid 44401481)
2. Schotte A, Bonaventure P, Janssen PF, Leysen JE. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: Risperidone compared with antipsychotics hitherto used. Jpn. J. Pharmacol. 1995 69 : 399 412. (Pubitemid 26013775)
3. Shiwa T, Amano T, Matsubayashi H, Seki T, Sasa M, Sakai N. Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J. Pharmacol. Sci. 2003 93 : 114 117. (Pubitemid 37254275)
4. Murasaki M, Koyama T, Machiyama Y et al. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: A comparative double-blind study with haloperidol. Rinsho Hyoka 1997 24 : 159 205 (in Japanese).
5. Kudo Y, Nakajima T, Saito M et al. Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl, on schizophrenia: A comparative double-blind study with mosapramine HCl. Rinsho Hyoka 1997 24 : 207 248 (in Japanese).
6. Fujita K, Fukuchi T, Yuasa S et al. Switch from risperidone to perospirone in patients with chronic schizophrenia. Clin. Drug Invest. 2004 24 : 295 299. (Pubitemid 38680230)
7. Sumiyoshi T. Clinical evaluation of perospirone in outpatients: Comparison with risperidone. Jpn. J. Clin. Psychopharmacol. 2003 6 : 895 904.
8. Fukuchi T, Yuasa S, Kitamura T. Clinical evaluation of long term SDA administration to outpatients with schizophrenia: Perospirone and risperidone. Seishin Igaku (Clin. Psychiatry) 2006 48 : 1229 1231.
9. Togo T, Iseki E, Shoji M et al. Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. J. Pharmacol. Sci. 2003 91 : 259 262. (Pubitemid 36575585)
10. Takeda T, Hashiba T, Sato S. The circadian changes in dopamine-2 receptor blockade of perospirone or risperidone. The serum prolactin response as the index. Jpn. J. Clin. Psychopharmacol. 2004 7 : 1511 1517.
11. World Health Organization. The International Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. World Health Organization, Geneva, 1993.
12. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987 13 : 261 276. (Pubitemid 18039085)
13. Inagaki A, Inada T, Fujii Y, Yagi G. Dose equivalence of psychotropic drugs. Part 4. Dose equivalence of orally administered neuroleptics (4). Rinsho Seishin Yakuri 1998 1 : 443 448 (in Japanese).
14. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr. Res. 2002 57 : 227 238. (Pubitemid 35240025)
15. Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J. Clin. Psychiatry 2003 64 (Suppl. 12 5 19.